Answer
VITRAKVI (larotrectinib sulfate) is preferably avoided during pregnancy as a precaution because there are no data on its use in pregnant women and, based on its mechanism of action, foetal harm cannot be excluded.
Sources for this answer
- Vitrakvi 25 mg hard capsulesBayer plc · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 14Document updated
Sources checked